Amicus Therapeutics, Inc.

Amicus Therapeutics, Inc.

FOLDNYSE / NASDAQHealthcareSmall cap

$14.49$0.00 (0.0%)

Last close · Data as of Apr 27, 2026

Market cap
$4.5B
P/E
-167.8x
EV / EBITDA
88.8x
Revenue
$634.2M
Net margin
-4.3%
ROCE
4.8%

Hidden because the last close is more than three trading days older than the latest prices of its class.

Amicus Therapeutics, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 27 Apr 2026 close.

1M
Stale
3M
Stale
6M
Stale
1Y
Stale
5Y
Stale
  • Hidden because the last close is more than three trading days older than the latest prices of its class.

52-week range

Day change $0.00 (0.0%) from $14.49 to $14.49 · Last close Apr 27, 2026

Best weekday to invest, historically

The same weekly amount in FOLD, bought on each weekday since 2021.

News & filings

What Amicus Therapeutics filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 27.1 million US dollars in fiscal 2025.

Strengths (1)

  • EBITDA grew 83.1% in fiscal 2025, 63.0 points more than revenue.
  • Prices are as of 27 Apr 2026; price-based points are paused until newer prices arrive.

Prices to the 27 Apr 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally.

Read moreShow less

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease; and DMX-200, a small molecule inhibitor of the chemokine receptor 2 that is in a pivotal Phase 3 study for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold; and Dimerix Limited for the commercialization of DMX-200 for the treatment of FSGS and other indications. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey. As of April 27, 2026, Amicus Therapeutics, Inc. operates as a subsidiary of BioMarin Pharmaceutical Inc.

Sector
Healthcare
Shares outstanding
310.9M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$4.5B
P/E
-167.8x
P/B
16.6x
EV / EBITDA
88.8x
EV / Sales
7.5x
P/S
7.2x
52-week high
$14.49
52-week low
$5.64

Profitability

Operating margin
5.4%
Net margin
-4.3%
EBITDA margin
8.5%
ROE
-9.9%
ROCE
4.8%
ROIC
6.0%
ROA
-2.9%
Asset turnover
0.67

Growth

Revenue
$634.2M
Revenue growth, 1Y
20.0%
Revenue CAGR, 3Y
24.4%
Net profit growth, 1Y
-51.7%
Free cash flow
$29.8M

Solvency

Current ratio
2.84
Debt / Equity
1.61
Debt / Assets
0.47
CFO / Net profit
-1.22
Cash / Market cap
4.7%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$634.2M
Cost of revenue$72.9M
Gross profit$561.3M
Operating expenses$526.8M
Research and development$135.8M
Selling, general and administrative$383.5M
Operating income$34.5M
Interest and other-$34.3M
Pretax income$190.0k
Tax and other$27.3M
Net income-$27.1M

Revenue and net profit

Revenue grew 20.0% in FY2025; net profit is the dashed line.

Amicus Therapeutics, Inc. revenue and net profit by fiscal year
Amicus Therapeutics, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$329.2M-$236.6M
FY2023$399.4M-$151.6M
FY2024$528.3M-$56.1M
FY2025$634.2M-$27.1M

Cash flows

FY2025: $33.1M from operations, $29.8M free after investment (dashed).

Amicus Therapeutics, Inc. operating and free cash flow by fiscal year
Amicus Therapeutics, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$166.6M-$170.3M
FY2023-$69.1M-$76.5M
FY2024-$33.9M-$37.4M
FY2025$33.1M$29.8M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$634.2M+20.0%1Y
EBITDA
$53.8M+83.1%1Y
Net profit
-$27.1M
Cash from operations
$33.1M
Free cash flow
$29.8M
Revenue CAGR, 3Y
24.4%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$634.2M$53.8M-$27.1M$29.8M-9.9%+20.0%-51.7%

Monthly returns

Month-by-month returns of FOLD across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$949.9M
Liabilities$675.6M
Equity$274.2M
Paid-in capital$3.0B
Retained earnings-$2.8B
Treasury stock$70.0k

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; FOLD highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

No company in this group has a positive P/E.

EV / Sales, for the companies without earnings

  1. Amicus Therapeutics, Inc. (this company)7.5x

Not shown (no positive earnings and no EV / Sales): Celcuity Inc., Erasca, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Amicus Therapeutics, Inc.FOLDthis company$4.5B-167.8x16.6x-9.9%88.8x
CG Oncology, Inc.CGON$4.9B-30.7x6.6x-21.4%-26.0x
Twist Bioscience CorporationTWST$4.6B-59.3x9.7x-16.4%-40.4x
Dianthus Therapeutics, Inc.DNTH$4.6B-28.3x9.3x-32.9%-25.6x
Celcuity Inc.CELC$4.5B-25.5x44.8x-176.1%-29.2x
Travere Therapeutics, Inc.TVTX$4.3B-168.1x37.4x-22.2%203.9x
10x Genomics, Inc.TXG$4.3B-97.7x5.3x-5.5%988.3x
Erasca, Inc.ERAS$4.1B-33.1x12.7x-38.3%-32.0x
LivaNova PLCLIVN$4.0B-16.7x3.4x-20.2%-34.4x
Peer median—-31.9x9.5x-21.8%-27.6x

Year-to-date ROI

FOLD since 1 January, against earlier years.

Historical volatility

FOLD's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Amicus Therapeutics, Inc. operating margin by fiscal year
Amicus Therapeutics, Inc. operating margin by fiscal year
DateOperating margin
FY2022-62.1%
FY2023-18.4%
FY20246.4%
FY20255.4%
LineFY2025
Cost of revenueCost Of Revenue$72.9M
Gross profitGross Profit$561.3M
Operating expensesOperating Expense$526.8M
Research and developmentResearch And Development$135.8M
Selling, general and administrativeSelling General And Administration$383.5M
Depreciation and amortisationDepreciation And Amortization In Income Statement$7.5M
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$7.5M
Total expensesTotal Expenses$599.7M
Pretax incomePretax Income$190.0k

Learn while you research

Academy chapters picked for Amicus Therapeutics, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Growth Investing20% revenue growth is in the top tier, learn how to value growth.7 min read
  3. 03 Leverage RatiosDebt/Equity of 1.61 is elevated, understand what that means for solvency.6 min read
  4. 04 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  5. 05 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  6. 06 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
Browse the full Equiscale Academy →